We are live on ! Find out more
FCM

Farallon Capital Management Portfolio holdings

AUM $21.7B
1-Year Est. Return 79.24%
This Fund
S&P 500
This Quarter Est. Return
-0.07%
1 Year Est. Return
+79.24%
3 Year Est. Return
+204.51%
5 Year Est. Return
+270.91%
10 Year Est. Return
+1,884.18%
AUM
$19.1B
AUM Growth
-$4.04B
Cap. Flow
-$3.24B
Cap. Flow %
-16.98%
Top 10 Hldgs %
50.33%
Holding
204
New
48
Increased
30
Reduced
30
Closed
31

Top Buys

Rank Stock Value
1
EA
Electronic Arts
EA
+$492M
2
AVGO icon
Broadcom
AVGO
+$292M
3
KKR icon
KKR & Co
KKR
+$280M
4
ROIV icon
Roivant Sciences
ROIV
+$248M
5
MA icon
Mastercard
MA
+$138M

Top Sells

Rank Stock Value
1
EXAS
Exact Sciences
EXAS
+$650M
2
CYBR
CyberArk
CYBR
+$470M
3
CRM icon
Salesforce
CRM
+$334M
4
NDAQ icon
Nasdaq
NDAQ
+$290M
5
RNAM
Avidity Biosciences
RNAM
+$233M

Sector Composition

Rank Sector Weight
1 Healthcare 46.53%
2 Communication Services 11.31%
3 Financials 11.23%
4 Technology 10.28%
5 Consumer Discretionary 4.69%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ARMK icon
26
Aramark
ARMK
$16.4B
$249M 1.3%
6,135,431
-3,221,615
-34% -$128M
BEAM icon
27
Beam Therapeutics
BEAM
$2.76B
$242M 1.27%
10,134,696
+71,585
+0.7% +$1.99M
DIS icon
28
Walt Disney
DIS
$184B
$231M 1.21%
2,401,591
-1,724,400
-42% -$182M
MA icon
29
Mastercard
MA
$499B
$217M 1.14%
435,071
+262,400
+152% +$138M
MCK icon
30
McKesson
MCK
$101B
$203M 1.06%
234,300
-64,600
-22% -$57.7M
AGIO icon
31
Agios Pharmaceuticals
AGIO
$2B
$192M 1.01%
5,684,000
+524,495
+10% +$14.9M
CNTA
32
DELISTED
Centessa Pharmaceuticals
CNTA
$191M 1%
4,809,000
-568,068
-11% -$14.5M
TNGX icon
33
Tango Therapeutics
TNGX
$4.32B
$190M 1%
9,097,411
-3,964,000
-30% -$55.2M
GRAL
34
GRAIL Inc
GRAL
$3.03B
$168M 0.88%
3,253,684
+911,000
+39% +$70.6M
TYRA icon
35
Tyra Biosciences
TYRA
$1.51B
$137M 0.72%
3,580,818
+1,514,000
+73% +$49M
THC icon
36
Tenet Healthcare
THC
$21.6B
$85.3M 0.45%
452,153
+80,000
+21% +$16.9M
CAH icon
37
Cardinal Health
CAH
$54.7B
$77.8M 0.41%
368,000
-208,000
-36% -$44.8M
PCVX icon
38
Vaxcyte
PCVX
$8.64B
$73.3M 0.38%
1,261,000
+1,256,000
+25,120% +$68.2M
DNTH icon
39
Dianthus Therapeutics
DNTH
$6.49B
$70.2M 0.37%
+836,000
New +$48.4M
BTSG icon
40
BrightSpring Health Services
BTSG
$12.2B
$68.9M 0.36%
1,617,000
+1,595,000
+7,250% +$64.3M
TWST icon
41
Twist Bioscience
TWST
$7.44B
$67.8M 0.36%
1,427,650
+1,420,000
+18,562% +$63.7M
BIDU icon
42
Baidu
BIDU
$35.2B
$49.4M 0.26%
443,785
+128,485
+41% +$17.4M
CGON icon
43
CG Oncology
CGON
$6.65B
$45.6M 0.24%
674,000
+666,000
+8,325% +$37.7M
AZN icon
44
AstraZeneca
AZN
$243B
$44.7M 0.23%
+226,499
New +$43.7M
MRK icon
45
Merck
MRK
$335B
$43.4M 0.23%
+361,000
New +$41.7M
ACHC icon
46
Acadia Healthcare
ACHC
$2.87B
$40.6M 0.21%
+1,736,800
New +$31.4M
WELL icon
47
Welltower
WELL
$170B
$39.5M 0.21%
200,000
-143,000
-42% -$28.3M
IMVT icon
48
Immunovant
IMVT
$8.64B
$38.4M 0.2%
1,546,000
+1,534,000
+12,783% +$39.7M
ENTA icon
49
Enanta Pharmaceuticals
ENTA
$383M
$36.3M 0.19%
2,871,862
+99,600
+4% +$1.34M
JNJ icon
50
Johnson & Johnson
JNJ
$627B
$36.2M 0.19%
+148,000
New +$34.5M
1
2
3 4 5

Similar funds

VARA
Value Aligned Research Advisors Princeton, New Jersey $20.7B AUM 292.88% 1-Year Est. Return
Tiger Global Management
Tiger Global Management New York $22.8B AUM 30.07% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return
Select Equity Group
Select Equity Group New York $19.5B AUM 17.33% 1-Year Est. Return
PCM
Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return
BPA
Beacon Pointe Advisors Newport Beach, California $18.9B AUM 18.9% 1-Year Est. Return
NAM
Nissay Asset Management Tokyo, Japan $18.9B AUM 27.21% 1-Year Est. Return
ASRS
Arizona State Retirement System Phoenix, Arizona $17.1B AUM 30.52% 1-Year Est. Return

Farallon Capital Management's Q1 2026 Portfolio in Review

As of Q1 2026, Farallon Capital Management held 204 positions worth $19.1B, down 17% from $23.1B the previous quarter. Its ten largest holdings account for 50% of the portfolio.

Farallon Capital Management withdrew a net $3.24B in Q1 2026, closing 31 positions and reducing 30 holdings. Its most notable exit was Exact Sciences, an estimated $650M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 47% of assets, up from 41% a quarter earlier, followed by Communication Services and Financials.

Against the trend, Farallon Capital Management opened a new position in Dianthus Therapeutics worth $70.2M.

  • Farallon Capital Management's largest Q1 2026 buy was Dianthus Therapeutics: 836,000 shares worth $70.2M.
  • Farallon Capital Management added most to Electronic Arts in Q1 2026, an estimated $492M increase.
  • Farallon Capital Management's biggest Q1 2026 reduction was Wabtec, cutting an estimated $210M.
  • Farallon Capital Management fully exited Exact Sciences in Q1 2026, selling an estimated $650M.
  • Farallon Capital Management's ten largest holdings make up 50% of its $19.1B portfolio in Q1 2026.
  • Farallon Capital Management opened 48 new positions and closed 31 in Q1 2026.
  • Farallon Capital Management's portfolio value fell 17% quarter-over-quarter to $19.1B.

Based on Farallon Capital Management's 13F filing for Q1 2026, filed 15 May 2026.